ArticleNano letters2014
A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins.
Article in Nano letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Bakuchiol-loaded amphiphilic polymeric nanoparticles: enhancing stability and multifunctionality through encapsulation.Journal of biological engineering · 2026Article
- Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.ACS pharmacology & translational science · 2024Article
- ROS-responsive PEGylated ferrocene polymer nanoparticles with improved stability for tumor-selective chemotherapy and imaging.Materials today. Bio · 2023Article
- Enhancement of bioactivity, thermal stability and tumor retention by self-fused concatenation of green fluorescent protein.Biochemistry and biophysics reports · 2021Article
- Targeted delivery of protein arginine deiminase-4 inhibitors to limit arterial intimal NETosis and preserve endothelial integrity.Cardiovascular research · 2021Article
- High Solubilization and Controlled Release of Paclitaxel Using Thermosponge Nanoparticles for Effective Cancer Therapy.Pharmaceutics · 2021Article
- Article
- Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies.Frontiers in bioengineering and biotechnology · 2020Review
- Bioinspired Heparin Nanosponge Prepared by Photo-crosslinking for Controlled Release of Growth Factors.Scientific reports · 2017Article
- Nanotechnology for protein delivery: Overview and perspectives.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Targeted nanoparticles for colorectal cancer.Nanomedicine (London, England) · 2016Review
- Article
- Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release.Chemical reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Protein therapeutics have gained attention recently for treatment of a myriad of human diseases due to their high potency and unique mechanisms of action. We present the development of a novel polymeric thermosponge nanoparticle for efficient delivery of labile proteins using a solvent-free polymer thermo-expansion mechanism with clinical potential, capable of effectively delivering a range of therapeutic proteins in a sustained manner with no loss of bioactivity, with improved biological half-lives and efficacy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.